The study compared AdvairA DiskusA, a combination of the LABA, salmeterol, and the inhaled corticosteroid (ICS), fluticasone propionate (FP), to FP monotherapy and showed that Advair
(FSC) had a safety profile comparable to FP when used to treat adolescent and adult patients with asthma, assessed by the composite endpoint of serious asthma-related events (deaths, intubations or hospitalisations).
Some big-selling products, like the respiratory medicine Advair
and the diabetes drug Victoza, have suffered precipitous declines in market share because Express Scripts, the biggest pharmacy benefits manager, recently stopped paying for them for many patients.
, GSK's blockbuster respiratory product, concerns over a generic version have dwindled given the FDA's increased scrutiny on finding the minimum effective dose of new products.
Glaxo is developing Relovair as a successor to its best- selling product, the Advair
Diskus (fluticasone propionate and salmeterol inhalation powder) inhalers were reported stolen in August 2009 and are not considered safe for use.
The patient stated that he preferred to receive a DPI of Advair
, an asthma treatment, generates approximately 25% of Glaxo's earnings.
An Advisory Committee to the FDA recently unanimously agreed (11 to 0) that GlaxoSmithKline's Advair
Diskus[R] 500/50 (fluticasone propionate and salmeterol inhalation powder) demonstrated a significant reduction in the risk of exacerbations in patients with chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in the US.
The survey asked each plan for information about restrictions on five drugs: Advair
, an asthma medication; Norvasc, a blood-pressure medication; Aciphex, a heartburn medication; Lexapro, an anti-depressant and anti-anxiety medication; and Ativan, another anti-anxiety medication.
Pharmaceuticals giant Glaxo-SmithKline yesterday said soaring sales of its asthma drug Advair
and diabetes medication Avandia drove profits up 16 per cent.
Sales of best-selling asthma drug Advair
surged by 22 per cent to more than pounds 3billion, while diabetes medication Avandia was up 18 per cent to pounds 1.
Investors will be interested in what GlaxoSmithKline has to say about asthma drug Advair
when it announces its full year results on Wednesday.